Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCF-BC1 for spontaneous osteonecrosis of the medial femoral condyle
jRCT2033260622Recruiting
- Sponsor
- Keio University Hospital
- Start
- Oct 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of KCF-BC1 in spontaneous osteonecrosis of the medial femoral condyle (SONK), sponsored by Keio University Hospital. Primary endpoint: Incidence of adverse events. Started Oct 2026; status: recruiting.
02
Drugs
KCF-BC1
03
Conditions
spontaneous osteonecrosis of the medial femoral condyle (SONK)
Beyond the preview
Go deeper on jRCT2033260622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260622.